Dr. Choon Yong Loo co-founded Group Ltd in 1976. He served as the Non-Independent Executive Chairman of Raffles Medical Group Ltd from 1997 until January 1, 2022, and has been its Executive Chairman and Ex...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qinghui Lu	Executive & Non-Independent Director	4.6yrs	Veri yok	0.0032% SGD 49.7k
Choon Yong Loo	Executive Chairman & CEO	no data	Veri yok	13.52% SGD 208.6m
Kimmy Goh	Company Secretary & Group Financial Controller	20yrs	Veri yok	Veri yok
Kah Ling Teo	Chief Information Officer	7yrs	Veri yok	Veri yok
Joanna Lee	Senior Manager of Communications	no data	Veri yok	Veri yok
Kenneth Wu	Chief Operating Officer of Singapore Healthcare	no data	Veri yok	Veri yok
Vincent Chia	Managing Director of Raffles China Healthcare	3yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: BSL 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qinghui Lu	Executive & Non-Independent Director	6.9yrs	Veri yok	0.0032% SGD 49.7k
Choon Yong Loo	Executive Chairman & CEO	35.7yrs	Veri yok	13.52% SGD 208.6m
Soo Nan Tan	Non-Executive & Non-Independent Director	24.5yrs	Veri yok	0.25% SGD 3.9m
Tse Ghow Lim	Non-Executive & Non-Independent Director	10.3yrs	Veri yok	0.028% SGD 436.6k
Yoong Keong Lew	Lead Independent Director	4.3yrs	Veri yok	0.011% SGD 165.9k
Cheong Boon Png	Non-Executive & Independent Director	6.3yrs	Veri yok	Veri yok
Sim Seng Lim	Non-Executive & Independent Director	1.4yrs	Veri yok	Veri yok
Wern-Yuen Tan	Non-Executive & Independent Director	3.5yrs	Veri yok	Veri yok
Chuan Neo Chong	Non-Executive & Independent Director	3.3yrs	Veri yok	Veri yok
Jao Yiu Sung	Independent Non-Executive Director	3.1yrs	Veri yok	Veri yok
Liangjian Lu	Non-Executive & Non-Independent Director	1.4yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BSL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/29 08:44
Gün Sonu Hisse Fiyatı	2025/01/28 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Raffles Medical Group Ltd 20 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Mak	CGS International
Patrick Yau	Citigroup Inc
Horng Han Low	CLSA

Raffles Medical Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Executive Chairman & CEO recently bought S$602k worth of stock

Executive Chairman & CEO recently bought S$861k worth of stock

Executive Chairman & CEO recently bought S$1.3m worth of stock

Executive Chairman & CEO recently bought S$979k worth of stock

Executive Chairman & CEO recently bought S$1.5m worth of stock

Executive Chairman & CEO recently bought S$700k worth of stock

Recent updates

Raffles Medical Group Ltd to Report Fiscal Year 2024 Results on Feb 24, 2025

Executive Chairman & CEO recently bought S$602k worth of stock

Executive Chairman & CEO recently bought S$861k worth of stock

Executive Chairman & CEO recently bought S$1.3m worth of stock

Executive Chairman & CEO recently bought S$979k worth of stock

Executive Chairman & CEO recently bought S$1.5m worth of stock

Executive Chairman & CEO recently bought S$700k worth of stock

New minor risk - Dividend sustainability

Executive Chairman & CEO recently bought S$1.3m worth of stock

First half 2024 earnings released: EPS: S$0.017 (vs S$0.032 in 1H 2023)

Executive Chairman & CEO recently bought S$1.5m worth of stock

Raffles Medical Group Ltd to Report First Half, 2024 Results on Jul 29, 2024

Raffles Medical Group (SGX:BSL) Is Reducing Its Dividend To SGD0.024

Executive Chairman & CEO recently bought S$500k worth of stock

Upcoming dividend of S$0.024 per share

Raffles Medical Group Ltd Approves One-Tier Tax Exempt Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Raffles Medical Group's (SGX:BSL) Dividend Is Being Reduced To SGD0.024

Raffles Medical Group's (SGX:BSL) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS misses analyst expectations

Now 20% undervalued

Raffles Medical Group Ltd Proposes Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Price target decreased by 12% to S$1.14

Consensus EPS estimates fall by 21%

Executive Chairman & CEO recently bought S$3.6m worth of stock

Dividend of S$0.024 announced

Raffles Medical Group Ltd, Annual General Meeting, Apr 26, 2024

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Investor sentiment deteriorates as stock falls 15%

Raffles Medical Group (SGX:BSL) Is Doing The Right Things To Multiply Its Share Price

Here's Why Raffles Medical Group (SGX:BSL) Has Caught The Eye Of Investors

Raffles Medical Group Ltd Announces Resignation of Soo Yu-Han Jessica as Joint Company Secretary, Effective 8 August 2023

High number of new directors

First half 2023 earnings released: EPS: S$0.032 (vs S$0.032 in 1H 2022)

Raffles Medical Group Ltd Announces Appointment of Lu Liangjian as Non-Executive and Non-Independent Director

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

Raffles Medical Group Ltd to Report First Half, 2023 Results on Jul 31, 2023

Raffles Medical Group (SGX:BSL) Could Easily Take On More Debt

A Look At The Fair Value Of Raffles Medical Group Ltd (SGX:BSL)

Is Now The Time To Put Raffles Medical Group (SGX:BSL) On Your Watchlist?

Upcoming dividend of S$0.038 per share at 2.6% yield

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To SGD0.038

Full year 2022 earnings: Revenues in line with analyst expectations

Raffles Medical Group (SGX:BSL) Might Have The Makings Of A Multi-Bagger

Price target increased by 8.1% to S$1.72

Full year 2022 earnings: EPS exceeds analyst expectations

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Raffles Medical Group Ltd to Report Fiscal Year 2022 Results on Feb 27, 2023

Returns At Raffles Medical Group (SGX:BSL) Are On The Way Up

Do Raffles Medical Group's (SGX:BSL) Earnings Warrant Your Attention?

Now 21% undervalued

Is There An Opportunity With Raffles Medical Group Ltd's (SGX:BSL) 25% Undervaluation?

Is Raffles Medical Group (SGX:BSL) A Risky Investment?

Now 21% undervalued

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case

Now 20% undervalued

Investor sentiment improved over the past week

Price target increased to S$1.52

Executive Chairman & CEO recently bought S$63k worth of stock

First half 2022 earnings released

Raffles Medical Group Ltd to Report First Half, 2022 Results on Aug 01, 2022

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of S$0.028 per share